Jinling Pharmaceutical Co Ltd (000919) - Total Liabilities
Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) has total liabilities worth CN¥1.18 Billion CNY (≈ $172.22 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000919 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Jinling Pharmaceutical Co Ltd - Total Liabilities Trend (1996–2024)
This chart illustrates how Jinling Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000919 total asset value.
Jinling Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jinling Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GnCenergy Co Ltd
KQ:119850
|
Korea | ₩149.30 Billion |
|
ION Exchange (India) Limited
NSE:IONEXCHANG
|
India | Rs20.40 Billion |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
China | CN¥399.05 Million |
|
Oculis Holding AG Ordinary shares
NASDAQ:OCS
|
USA | $39.94 Million |
|
Leong Hup International Berhad
KLSE:6633
|
Malaysia | RM3.27 Billion |
|
Korea District Heating Corp
KO:071320
|
Korea | ₩5.38 Trillion |
|
Zhangjiagang Furui Special Equip
SHE:300228
|
China | CN¥1.52 Billion |
|
Allied Electronics Corporation Ltd
JSE:AEL
|
South Africa | ZAC4.25 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Jinling Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 000919 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jinling Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jinling Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual total liabilities of Jinling Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.24 Billion ≈ $181.49 Million |
+43.29% |
| 2023-12-31 | CN¥865.58 Million ≈ $126.66 Million |
-5.54% |
| 2022-12-31 | CN¥916.30 Million ≈ $134.08 Million |
+0.35% |
| 2021-12-31 | CN¥913.10 Million ≈ $133.61 Million |
+7.37% |
| 2020-12-31 | CN¥850.43 Million ≈ $124.44 Million |
+15.92% |
| 2019-12-31 | CN¥733.62 Million ≈ $107.35 Million |
+14.83% |
| 2018-12-31 | CN¥638.90 Million ≈ $93.49 Million |
-20.45% |
| 2017-12-31 | CN¥803.11 Million ≈ $117.52 Million |
-0.22% |
| 2016-12-31 | CN¥804.90 Million ≈ $117.78 Million |
-13.05% |
| 2015-12-31 | CN¥925.73 Million ≈ $135.46 Million |
+6.25% |
| 2014-12-31 | CN¥871.24 Million ≈ $127.49 Million |
+19.36% |
| 2013-12-31 | CN¥729.94 Million ≈ $106.81 Million |
-0.43% |
| 2012-12-31 | CN¥733.12 Million ≈ $107.28 Million |
+15.81% |
| 2011-12-31 | CN¥633.01 Million ≈ $92.63 Million |
+16.26% |
| 2010-12-31 | CN¥544.47 Million ≈ $79.67 Million |
+35.92% |
| 2009-12-31 | CN¥400.59 Million ≈ $58.62 Million |
+23.54% |
| 2008-12-31 | CN¥324.25 Million ≈ $47.45 Million |
-22.21% |
| 2007-12-31 | CN¥416.86 Million ≈ $61.00 Million |
+26.17% |
| 2006-12-31 | CN¥330.39 Million ≈ $48.35 Million |
+17.82% |
| 2005-12-31 | CN¥280.42 Million ≈ $41.03 Million |
-13.14% |
| 2004-12-31 | CN¥322.83 Million ≈ $47.24 Million |
+26.08% |
| 2003-12-31 | CN¥256.06 Million ≈ $37.47 Million |
-13.72% |
| 2002-12-31 | CN¥296.79 Million ≈ $43.43 Million |
-3.18% |
| 2001-12-31 | CN¥306.54 Million ≈ $44.86 Million |
+89.97% |
| 2000-12-31 | CN¥161.37 Million ≈ $23.61 Million |
+5.30% |
| 1999-12-31 | CN¥153.24 Million ≈ $22.42 Million |
+28.09% |
| 1998-12-31 | CN¥119.63 Million ≈ $17.51 Million |
+49.12% |
| 1997-12-31 | CN¥80.23 Million ≈ $11.74 Million |
+3.85% |
| 1996-12-31 | CN¥77.25 Million ≈ $11.30 Million |
-- |
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more